Physician profile
April White
NPI 1720655483
$2,768.37
in general payments reported to CMS, 2019-2025
28 companies · $71.86 in 2025
The $71.86 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $312 · 2022: $1,407 · 2023: $645 · 2024: $332 · 2025: $71.86.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,049.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,048.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $396.17 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $268.44 | 2021-2024 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $230.14 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $168.34 | 2021-2024 | |
| Lilly USA, LLC | $163.55 | 2022-2023 | Mounjaro |
| Abbvie INC. | $158.75 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $152.44 | 2021-2024 | Jardiance |
| Sanofi-Aventis U.S. LLC | $144.41 | 2021-2022 | |
| Glaxosmithkline, LLC. | $135.13 | 2022-2024 | Trelegy Ellipta, Shingrix |
| Amarin Pharma, INC. | $131.24 | 2021-2022 | |
| Medtronic, INC. | $126.14 | 2022 | |
| Novartis Pharmaceuticals Corporation | $115.11 | 2022-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $106.25 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.67 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $52.11 | 2022-2023 | Quviviq |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $48.18 | 2023-2024 | Repatha, Otezla |
| Merck Sharp & Dohme LLC | $46.54 | 2021-2023 | Verquvo, Belsomra |
| Xeris Pharmaceuticals, INC. | $34.73 | 2023 | Gvoke Hypopen |
| Almatica Pharma LLC | $30.63 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $29.62 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $25.23 | 2021-2022 | |
| Evofem Biosciences, INC. | $24.02 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $23.12 | 2022 | |
| Dexcom, INC. | $21.85 | 2023 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $21.70 | 2023 | Rexulti |
| Exact Sciences Corporation | $16.31 | 2024 | Cologuard Collection Kit |
| Mylan Specialty L.P. | $14.72 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $12.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw April White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.